Investors
Aer Therapeutics is developing high-value, novel treatments for muco-obstructive lung diseases.
Investing in the Future of Respiratory Innovation
AER-01 is the first treatment that targets mucus plugs in patients with muco-obstructive lung disease. It is an area that is currently underserved by existing pharmaceutical treatments that focus on bronchoconstriction and inflammation.
AER-01 has clear market potential to reach the approximately 5 million severe COPD patients and 1.5 million severe asthmatics who are affected by mucus plugs.
AER-01 is positioned to become the standard of care for the treatment of obstructive lung diseases in addition to current treatments such as bronchodilators and steroid therapy.
Investor Presentation
Aer Therapeutics Corporate Presentation
To learn more about Aer Therapeutics and our clinical trials, request a copy of our corporate presentation.
Study AER-01-002 is using a novel and precision imaging strategy to enroll 100
Supported by premier life science industry investors Canaan, OrbiMed, and Hatteras Venture Partners
Supported by premier life science industry investors Canaan, OrbiMed, and Hatteras Venture Partners